Search

Your search keyword '"Louise A.A. Gerbens"' showing total 4 results
Start Over Author "Louise A.A. Gerbens"
4 results on '"Louise A.A. Gerbens"'

1. Consensus on the therapeutic management of atopic dermatitis ‒ Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique

Author

Raquel Leao Orfali, Daniel Lorenzini, Aline Bressan, Anber Ancel Tanaka, Ana Maria Mósca de Cerqueira, André da Silva Hirayama, Andréa Machado Coelho Ramos, Carolina Contin Proença, Claudia Marcia de Resende Silva, Cristina Marta Maria Laczynski, Francisca Regina Carneiro, Gleison Duarte, Gunter Hans Filho, Heitor de Sá Gonçalves, Ligia Pessoa de Melo, Luna Azulay-Abulafia, Magda Blessmann Weber, Maria Cecília Rivitti-Machado, Mariana Colombini Zaniboni, Marília Ogawa, Mario Cezar Pires, Mayra Ianhez, Paulo Antonio Oldani Felix, Renan Bonamigo, Roberto Takaoka, Rosana Lazzarini, Silmara Cestari, Silvia Assumpção Soutto Mayor, Tania Cestari, Zilda Najjar Prado de Oliveira, Phyllis I. Spuls, Louise A.A. Gerbens, and Valeria Aoki

Subjects
Atopic dermatitis, Delphi technique, Medication therapy management, Phototherapy, Dermatology, RL1-803
Abstract

Abstract This publication is an update of the “Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology” published in 2019, considering the novel, targeted-oriented systemic therapies for atopic dermatitis. The initial recommendations of the current consensus for systemic treatment of patients with atopic dermatitis were based on a recent review of scientific published data and a consensus was reached after voting. The Brazilian Society of Dermatology invited 31 experts from all regions of Brazil and 2 international experts on atopic dermatitis who fully contributed to the process. The methods included an e-Delphi study to avoid bias, a literature search and a final consensus meeting. The authors added novel approved drugs in Brazil and the indication for phototherapy and systemic therapy for AD. The therapeutical response to systemic treatment is hereby reported in a suitable form for clinical practice and is also part of this updated manuscript.

Published
2023
Full Text
View/download PDF

2. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesCapsule Summary

Author

Angela L. Bosma, MD, Wouter Ouwerkerk, PhD, Madeline J. Heidema, MD, David Prieto-Merino, PhD, Michael R. Ardern-Jones, MD, PhD, Paula Beattie, MD, Sara J. Brown, MD, PhD, John R. Ingram, MD, PhD, Alan D. Irvine, MD, DSc, Graham Ogg, MD, PhD, Prakash Patel, BSc, Nick J. Reynolds, MD, PhD, R.M. Ross Hearn, MD, Mandy Wan, PhD, Richard B. Warren, MD, PhD, Richard T. Woolf, MD, PhD, Ariënna M. Hyseni, Louise A.A. Gerbens, MD, PhD, Phyllis I. Spuls, MD, PhD, Carsten Flohr, MD, PhD, and Maritza A. Middelkamp-Hup, MD, PhD

Subjects
atopic dermatitis, atopic eczema, ciclosporin, daily practice, dupilumab, effectiveness, Dermatology, RL1-803
Abstract

Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. Methods: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated. Results: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P .05). Limitations: Unblinded, non-randomized. Conclusion: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.

Published
2023
Full Text
View/download PDF

3. The HOME Core outcome set for clinical trials of atopic dermatitis

Author

Hywel C. Williams, Jochen Schmitt, Kim S. Thomas, Phyllis I. Spuls, Eric L. Simpson, Christian J. Apfelbacher, Joanne R. Chalmers, Masutaka Furue, Norito Katoh, Louise A.A. Gerbens, Yael A. Leshem, Laura Howells, Jasvinder A. Singh, Maarten Boers, Dermatology, AII - Inflammatory diseases, APH - Methodology, APH - Quality of Care, APH - Personalized Medicine, Lee Kong Chian School of Medicine (LKCMedicine), Epidemiology and Data Science, and Rheumatology

Subjects
Adult, clinical trials, Immunology, Eczema, Infant, Atopic Dermatitis, core outcome sets, Severity of Illness Index, Dermatitis, Atopic, Outcome Assessment, Health Care, Quality of Life, Humans, Immunology and Allergy, Medicine [Science], Child, Atopic dermatitis
Abstract

Core outcome sets are critically important outcomes that should be measured in clinical trials. Their absence in atopic dermatitis is a form of research waste and impedes combining evidence to inform patient care. Here, we articulate the rationale for core outcome sets in atopic dermatitis and review the work of the international Harmonising Outcome Measures for Eczema group from its inception in Munich, 2010. We describe core domain determination (what should be measured), to instrument selection (how domains should be measured), culminating in the complete core outcome measurement set in Tokyo, 2019. Using a "road map," Harmonising Outcome Measures for Eczema includes diverse research methods including Delphi and nominal group techniques informed by systematic reviews of properties of candidate instruments. The 4 domains and recommended instruments for including in all clinical trials of atopic dermatitis are patient symptoms, measured by Patient-Oriented Eczema Measure and peak Numerical Rating Scale 11 for itch intensity over 24 hours, clinical signs measured using the Eczema Area and Severity Index, quality of life measured by the Dermatology Life Quality Index series for adults, children, and infants, and long-term control measured by either Recap of atopic eczema or Atopic Dermatitis Control Tool. Published version Details of funding for each of the consensus meetings is outlined in the published meeting reports. The following additional funding sources contributed to facilitating the HOME COS development: National Institute for Health and Care Research Senior Investigator award to Prof Hywel Williams (RE 2374) funded travel costs to enable UK patients to participate in HOME meetings; National Institute for Health and Care Research Programme Grant for Applied Research RP-PG-0407-10177 ‘‘Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)’’ was used to support completion of the some of the systematic reviews, the cost of meetings and patient and public involvement (Prof Kim Thomas); NIH NIAMS A Community-based Assessment of Skin Care, Allergies, and Eczema: The CASCADE Trial grant number 5 R01 AR071057-05 and Oregon Clinical and Translational Research Institute (OCTRI) assisted with outcome evaluations and associated travel costs (Prof Eric Simpson); Laura Howells received a PhD studentship from the British Skin Foundation (Ref: 8016) for studies that informed this work.

Published
2022
Full Text
View/download PDF

4. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types

Author

Angela L. Bosma, Wouter Ouwerkerk, Madeline J. Heidema, David Prieto-Merino, Michael R. Ardern-Jones, Paula Beattie, Sara J. Brown, John R. Ingram, Alan D. Irvine, Graham Ogg, Prakash Patel, Nick J. Reynolds, R.M. Ross Hearn, Mandy Wan, Richard B. Warren, Richard T. Woolf, Ariënna M. Hyseni, Louise A.A. Gerbens, Phyllis I. Spuls, Carsten Flohr, Maritza A. Middelkamp-Hup, Epidemiology and Data Science, AII - Cancer immunology, CCA - Cancer Treatment and Quality of Life, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Dermatology, APH - Methodology, APH - Personalized Medicine, AII - Inflammatory diseases, APH - Quality of Care, and AII - Infectious diseases

Subjects
safety, atopic dermatitis, atopic eczema, effectiveness, Dermatology, systemic treatment, registry, methotrexate, ciclosporin, dupilumab, morphology, ethnicity, daily practice, race, routine clinical care, skin type
Abstract

Background: few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types.Objective: to investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type.Methods: in an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated.Results: a total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P < .001), more often had follicular eczema (22.1% vs 2.6%; P < .001), higher baseline Eczema Area and Severity Index (EASI) scores (20.1 vs 14.9; P = .009), less allergic contact dermatitis (30.9% vs 47.4%; P = .03), and less previous phototherapy use (39.7% vs 59.0%; P = .008). When comparing DST and LST corrected for covariates including baseline EASI, DST showed greater mean EASI reduction between baseline and 6 months with only dupilumab (16.7 vs 9.7; adjusted P = .032). No differences were found for adverse events for any treatments (P > .05).Limitations: unblinded, non-randomized.Conclusions: atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results